findmyKOL

Laurence Sperling, MD

Basic profile

Emory University

ORCIDNPI
RegionAtlanta, GA · SoutheastSpecialtyCardiovascular DiseaseFocusCardiology
ActivityNot yet indexedEmergingfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publicationSee ScholarshipOnline presenceNot yet checkedPaymentsNone reportedNIH fundingNot yet indexedWhy? →

Laurence Sperling is a Cardiology physician affiliated with Emory University. OpenAlex indexes 520 publications with 32,332 citations (h-index 68); ClinicalTrials.gov lists 1 registered study matched to this name. By OpenAlex citation count, this profile ranks in the top 5% of Cardiovascular Disease profiles in the findmyKOL directory.

Overview

Scholarship

indexed output and impact (OpenAlex)
520publications

Distinct works indexed by OpenAlex, matched via ORCID.

32,332citations

Total citations across indexed works.

68h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
1clinical trials

Investigator role on registered studies.

View trials

Clinical trials

Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.

Medicare prescribing footprint (2023)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cardiovascular

    87.8%
    Statin25.1%
    Atorvastatin Calcium50%Rosuvastatin Calcium34%Pravastatin Sodium12%Simvastatin5%
    Part D<11 patients
    Beta blocker17.3%
    Carvedilol46%Metoprolol Succinate36%Metoprolol Tartrate18%
    Part D46 patients

    + 11 more classes in this area

  • Blood & clotting

    10.2%
    Factor Xa inhibitor7.4%
    Eliquis100%
    Part D37 patients
    P2Y12 inhibitor2.8%
    Clopidogrel100%
    Part D20 patients
  • Metabolism & gastrointestinal

    2%
    Potassium supplement1.1%
    Potassium Chloride100%
    Part D<11 patients
    SGLT2 inhibitor1%
    Farxiga100%
    Part D<11 patients
Where care is delivered (Part B)0% facility · 100% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”